-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In August, various companies disclosed their interim performance reports.
On August 23, hundreds of companies released their performance reports for the first half of 2022, including 17 pharmaceutical companies
.
Among these 17 pharmaceutical companies, 5 companies, Kaili Medical, Yingkang Life, Jidan Bio, China Resources Double Crane, and China Resources Sanjiu, achieved double growth in revenue and net profit
.
According to the 2022 semi-annual report released by Kaili Medical
.
In the first half of this year, the company's operating income increased by 30% year-on-year to 836 million yuan, and the net profit attributable to shareholders of listed companies after deductions increased by 78.
38% year-on-year to 163 million yuan
.
From the perspective of revenue ratio, color ultrasound is still a major existing medical business.
In the first half of the year, the operating income increased by 25.
59% year-on-year to 543 million yuan, and the gross profit margin was 63.
52%
.
In addition, in the first half of the year, the revenue of endoscopes and endoscopic therapeutic devices increased by 51.
47% year-on-year to 272 million yuan, with a gross profit margin of 69.
76%, a year-on-year increase of 4.
53%
.
According to the data, the business of Kaili Medical is mainly divided into two categories: color Doppler ultrasound, endoscope and endoscopic treatment equipment
.
Relevant persons said that since 2021, the company's ultrasound and endoscopic products have performed relatively positively in tertiary hospitals, and this year has doubled year-on-year
.
From the perspective of customer classification, these orders are mainly from new orders from developed hospitals.
High-end products are more and more recognized, and they have the ability to challenge imported brands in the future
.
At present, some complex surgical scopes of endoscope are still lacking and need to be supplemented as soon as possible
.
According to the 2022 semi-annual report released by Yingkang Life, in the first half of the year, the company's total operating income increased by 7.
34% year-on-year to 575 million yuan; the net profit attributable to shareholders of listed companies increased by 13.
71% year-on-year to 47.
2898 million yuan; The net profit attributable to shareholders of the listed company after deduction of non-fees increased by 715.
34% year-on-year to 45.
05 million yuan
.
Among them, the operating income of medical devices was 58.
42 million yuan, a sharp rebound year-on-year, an increase of 172.
29%, and the medical service revenue was 516 million yuan, a year-on-year increase of 0.
46%
.
It is mentioned in the report that Yingkang Life insists on accelerating the layout and development of the whole industry chain of tumor pre-diagnosis/treatment/health care
.
Under the epidemic situation, while strictly adhering to the medical bottom line, ensuring the quality of medical services, and actively fulfilling social responsibilities, its hospitals have improved the efficiency of operation and management, and achieved contrarian growth in revenue and net profit
.
It is reported that in recent years, Yingkang Life has been deployed around five major economic circles, and has continued to promote the implementation of regional medical centers.
Among them, Sichuan Friendship Hospital and Chengdu Meinian Health have jointly established a medical consortium; the second phase of Suzhou Guangci Hospital is steadily advancing; Yuncheng First Hospital has established a medical consortium network covering more than 50 medical institutions
.
According to the 2022 semi-annual report released by Basic Egg, in the first half of the year, the company’s operating income increased by 62.
12% year-on-year to 973 million yuan; the net profit attributable to shareholders of the listed company increased by 93.
03% year-on-year to 329.
8 million yuan
.
Basic Egg is mainly engaged in the research and development, production and sales of in vitro diagnostic products.
During the reporting period, Basic Egg achieved an in vitro diagnostic business income of 831 million yuan, a substantial increase of 90.
04% over last year
.
The rapid growth of in vitro diagnostic reagents was mainly driven by the sales growth of the company's self-produced products; the POCT product line achieved an operating income of 756 million yuan, an increase of 95.
99% over the same period of the previous year
.
There are more than 2,000 installed POCT instruments, including 920+ hospitals of second-level and above
;
According to the 2022 semi-annual report released by China Resources Shuanghe, in the first half of the year, the company’s operating income increased by 6.
07% year-on-year to 4.
911 billion yuan; net profit attributable to the parent increased by 23.
89% year-on-year to 737 million yuan
.
According to the data, the main business of China Resources Double-Crane covers new drug research and development, preparation production, drug sales, pharmaceutical equipment and API production.
The platform is deeply engaged in the fields of chronic diseases, infusion, pediatrics, nephrology, mental/neural and other fields
.
The report shows that in the first half of the year, the company's chronic disease business revenue increased by 8% year-on-year
.
The revenue of differentiated chronic disease products that are not centrally sourced increased by 5%, of which: the revenue of No.
0 core product in the antihypertensive field increased by 4% year-on-year, the revenue of hypoglycemic drug Tangshiping increased by 16% year-on-year, and the cerebrovascular drug Citicoline Sodium Tablets Sales volume increased by 6% year-on-year
.
Revenue from national centralized procurement of chronic disease products increased by 26%; revenue from specialist business increased by 2% year-on-year; revenue in the field of pediatric drugs remained flat year-on-year.
According to the 2022 semi-annual report released by China Resources Sanjiu, the company’s operating income in the first half of the year increased by 6.
82% year-on-year.
%, was 8.
401 billion yuan; net profit attributable to the parent increased by 4.
16% year-on-year to 1.
433 billion yuan
.
The company's overall operating performance in the first half of the year performed well, mainly due to the growth of CHC business
.
The report shows that in the first half of the year, the company's CHC health consumer goods business achieved a year-on-year increase of 7.
43% in operating income to 5.
535 billion yuan
.
In addition, the operating income of the prescription drug business increased by 5.
68% year-on-year to 2.
498 billion yuan.
The company said that the formula granule business was affected by the national standard switching and the speed of the provincial standard promotion, and the growth rate declined to a certain extent, and the traditional Chinese medicine injection business was affected by the epidemic and centralized procurement policies.
The year-on-year decline in sales affected the growth rate of the prescription drug business
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
On August 23, hundreds of companies released their performance reports for the first half of 2022, including 17 pharmaceutical companies
.
Among these 17 pharmaceutical companies, 5 companies, Kaili Medical, Yingkang Life, Jidan Bio, China Resources Double Crane, and China Resources Sanjiu, achieved double growth in revenue and net profit
.
According to the 2022 semi-annual report released by Kaili Medical
.
In the first half of this year, the company's operating income increased by 30% year-on-year to 836 million yuan, and the net profit attributable to shareholders of listed companies after deductions increased by 78.
38% year-on-year to 163 million yuan
.
From the perspective of revenue ratio, color ultrasound is still a major existing medical business.
In the first half of the year, the operating income increased by 25.
59% year-on-year to 543 million yuan, and the gross profit margin was 63.
52%
.
In addition, in the first half of the year, the revenue of endoscopes and endoscopic therapeutic devices increased by 51.
47% year-on-year to 272 million yuan, with a gross profit margin of 69.
76%, a year-on-year increase of 4.
53%
.
According to the data, the business of Kaili Medical is mainly divided into two categories: color Doppler ultrasound, endoscope and endoscopic treatment equipment
.
Relevant persons said that since 2021, the company's ultrasound and endoscopic products have performed relatively positively in tertiary hospitals, and this year has doubled year-on-year
.
From the perspective of customer classification, these orders are mainly from new orders from developed hospitals.
High-end products are more and more recognized, and they have the ability to challenge imported brands in the future
.
At present, some complex surgical scopes of endoscope are still lacking and need to be supplemented as soon as possible
.
According to the 2022 semi-annual report released by Yingkang Life, in the first half of the year, the company's total operating income increased by 7.
34% year-on-year to 575 million yuan; the net profit attributable to shareholders of listed companies increased by 13.
71% year-on-year to 47.
2898 million yuan; The net profit attributable to shareholders of the listed company after deduction of non-fees increased by 715.
34% year-on-year to 45.
05 million yuan
.
Among them, the operating income of medical devices was 58.
42 million yuan, a sharp rebound year-on-year, an increase of 172.
29%, and the medical service revenue was 516 million yuan, a year-on-year increase of 0.
46%
.
It is mentioned in the report that Yingkang Life insists on accelerating the layout and development of the whole industry chain of tumor pre-diagnosis/treatment/health care
.
Under the epidemic situation, while strictly adhering to the medical bottom line, ensuring the quality of medical services, and actively fulfilling social responsibilities, its hospitals have improved the efficiency of operation and management, and achieved contrarian growth in revenue and net profit
.
It is reported that in recent years, Yingkang Life has been deployed around five major economic circles, and has continued to promote the implementation of regional medical centers.
Among them, Sichuan Friendship Hospital and Chengdu Meinian Health have jointly established a medical consortium; the second phase of Suzhou Guangci Hospital is steadily advancing; Yuncheng First Hospital has established a medical consortium network covering more than 50 medical institutions
.
According to the 2022 semi-annual report released by Basic Egg, in the first half of the year, the company’s operating income increased by 62.
12% year-on-year to 973 million yuan; the net profit attributable to shareholders of the listed company increased by 93.
03% year-on-year to 329.
8 million yuan
.
Basic Egg is mainly engaged in the research and development, production and sales of in vitro diagnostic products.
During the reporting period, Basic Egg achieved an in vitro diagnostic business income of 831 million yuan, a substantial increase of 90.
04% over last year
.
The rapid growth of in vitro diagnostic reagents was mainly driven by the sales growth of the company's self-produced products; the POCT product line achieved an operating income of 756 million yuan, an increase of 95.
99% over the same period of the previous year
.
There are more than 2,000 installed POCT instruments, including 920+ hospitals of second-level and above
;
According to the 2022 semi-annual report released by China Resources Shuanghe, in the first half of the year, the company’s operating income increased by 6.
07% year-on-year to 4.
911 billion yuan; net profit attributable to the parent increased by 23.
89% year-on-year to 737 million yuan
.
According to the data, the main business of China Resources Double-Crane covers new drug research and development, preparation production, drug sales, pharmaceutical equipment and API production.
The platform is deeply engaged in the fields of chronic diseases, infusion, pediatrics, nephrology, mental/neural and other fields
.
The report shows that in the first half of the year, the company's chronic disease business revenue increased by 8% year-on-year
.
The revenue of differentiated chronic disease products that are not centrally sourced increased by 5%, of which: the revenue of No.
0 core product in the antihypertensive field increased by 4% year-on-year, the revenue of hypoglycemic drug Tangshiping increased by 16% year-on-year, and the cerebrovascular drug Citicoline Sodium Tablets Sales volume increased by 6% year-on-year
.
Revenue from national centralized procurement of chronic disease products increased by 26%; revenue from specialist business increased by 2% year-on-year; revenue in the field of pediatric drugs remained flat year-on-year.
According to the 2022 semi-annual report released by China Resources Sanjiu, the company’s operating income in the first half of the year increased by 6.
82% year-on-year.
%, was 8.
401 billion yuan; net profit attributable to the parent increased by 4.
16% year-on-year to 1.
433 billion yuan
.
The company's overall operating performance in the first half of the year performed well, mainly due to the growth of CHC business
.
The report shows that in the first half of the year, the company's CHC health consumer goods business achieved a year-on-year increase of 7.
43% in operating income to 5.
535 billion yuan
.
In addition, the operating income of the prescription drug business increased by 5.
68% year-on-year to 2.
498 billion yuan.
The company said that the formula granule business was affected by the national standard switching and the speed of the provincial standard promotion, and the growth rate declined to a certain extent, and the traditional Chinese medicine injection business was affected by the epidemic and centralized procurement policies.
The year-on-year decline in sales affected the growth rate of the prescription drug business
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
